<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Determination That COGENTIN (Benztropine Mesylate) Injection, 1 Milligram per 1 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Determination That COGENTIN (Benztropine Mesylate) Injection, 1 Milligram per 1 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness</h1>
    <div class="metadata">Published: 2026-02-05 12:24:48</div>
    <div class="summary">The Food and Drug Administration (FDA or the Agency) has determined that COGENTIN (benztropine mesylate) Injection, 1 milligram (mg)/1 milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2023/11/13/2023-24882/determination-that-cogentin-benztropine-mesylate-injection-1-milligram-per-1-milliliter-was-not" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2023/11/13/2023-24882/determination-that-cogentin-benztropine-mesylate-injection-1-milligram-per-1-milliliter-was-not</a></div>
</body>
</html>
